Agilent's Opdivo CDx Gets Expanded CE Mark in Europe

Jun 16, 2017

NEW YORK (GenomeWeb) – Agilent Technologies announced today that its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab), has has received an expanded CE mark for use in Europe.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul

10

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Main menu